[
    [
        {
            "time": "",
            "orginal_text": "药明康德(02359)调整2018年A股激励计划授予的限制性A股股票回购数量和回购价格",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股激励计划",
                    "限制性股票",
                    "回购数量",
                    "回购价格"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德(02359)调整2018年A股激励计划授予的限制性A股股票回购数量和回购价格",
            "scores": {
                "News_content": "药明康德(02359)调整2018年A股激励计划授予的限制性A股股票回购数量和回购价格",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-07-01",
            "orginal_text": "药明康德(603259.SH)826万股限制性股票将于7月1日上市流通",
            "features": {
                "keywords": [
                    "药明康德",
                    "限制性股票",
                    "上市流通",
                    "解禁"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德(603259.SH)826万股限制性股票将于7月1日上市流通",
            "scores": {
                "News_content": "药明康德(603259.SH)826万股限制性股票将于7月1日上市流通",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "北向资金本周爆买A股超200亿，连续加码金融股",
            "features": {
                "keywords": [
                    "北向资金",
                    "A股",
                    "金融股",
                    "加码"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金本周爆买A股超200亿，连续加码金融股",
            "scores": {
                "News_content": "北向资金本周爆买A股超200亿，连续加码金融股",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医疗板块逆势拉升，国际医学、通策医疗涨超5%",
            "features": {
                "keywords": [
                    "医疗板块",
                    "逆势拉升",
                    "国际医学",
                    "通策医疗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医疗板块逆势拉升，国际医学、通策医疗涨超5%",
            "scores": {
                "News_content": "医疗板块逆势拉升，国际医学、通策医疗涨超5%",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "北向资金大幅加仓光伏龙头，甩卖白酒股与医药股",
            "features": {
                "keywords": [
                    "北向资金",
                    "光伏龙头",
                    "加仓",
                    "甩卖",
                    "白酒股",
                    "医药股"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金大幅加仓光伏龙头，甩卖白酒股与医药股",
            "scores": {
                "News_content": "北向资金大幅加仓光伏龙头，甩卖白酒股与医药股",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "百时美施贵宝布局阿尔茨海默病，合作开发创新Tau蛋白抗体",
            "features": {
                "keywords": [
                    "百时美施贵宝",
                    "阿尔茨海默病",
                    "Tau蛋白抗体"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "百时美施贵宝布局阿尔茨海默病，合作开发创新Tau蛋白抗体",
            "scores": {
                "News_content": "百时美施贵宝布局阿尔茨海默病，合作开发创新Tau蛋白抗体",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "艾伯维收购BCMA双特异性抗体疗法，治疗多发性骨髓瘤",
            "features": {
                "keywords": [
                    "艾伯维",
                    "BCMA双特异性抗体",
                    "多发性骨髓瘤"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "艾伯维收购BCMA双特异性抗体疗法，治疗多发性骨髓瘤",
            "scores": {
                "News_content": "艾伯维收购BCMA双特异性抗体疗法，治疗多发性骨髓瘤",
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "Kras抑制剂获FDA突破性疗法认定，再鼎拥有大中华区开发权益",
            "features": {
                "keywords": [
                    "Kras抑制剂",
                    "FDA",
                    "突破性疗法",
                    "再鼎",
                    "大中华区"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "Kras抑制剂获FDA突破性疗法认定，再鼎拥有大中华区开发权益",
            "scores": {
                "News_content": "Kras抑制剂获FDA突破性疗法认定，再鼎拥有大中华区开发权益",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]